Solid Biosciences Inc./$SLDB
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Ticker
$SLDB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
100
ISIN
US83422E2046
Website
SLDB Metrics
BasicAdvanced
$495M
-
-$2.92
2.33
-
Price and volume
Market cap
$495M
Beta
2.33
52-week high
$6.85
52-week low
$2.41
Average daily volume
1.8M
Financial strength
Current ratio
10.89
Quick ratio
10.665
Long term debt to equity
7.017
Total debt to equity
8.023
Interest coverage (TTM)
-456.61%
Profitability
EBITDA (TTM)
-140.383
Management effectiveness
Return on assets (TTM)
-30.15%
Return on equity (TTM)
-55.30%
Valuation
Price to book
1.68
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
-2.85
Free cash flow yield (TTM)
-35.08%
Free cash flow per share (TTM)
-224.18%
Growth
Earnings per share change (TTM)
-20.68%
3-year earnings per share growth (CAGR)
-35.23%
Bulls say / Bears say
Solid Biosciences received FDA IND and Health Canada CTA approvals for SGT-501, a novel gene therapy targeting Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), indicating regulatory confidence in their pipeline. (globenewswire.com)
The company reported positive initial data from the INSPIRE DUCHENNE Phase 1/2 trial for SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy, suggesting potential efficacy. (globenewswire.com)
Analysts have given Solid Biosciences a consensus 'Buy' rating with an average price target of $15.30, reflecting strong market confidence. (marketbeat.com)
Despite positive trial data, Solid Biosciences' stock price has experienced volatility, with a 3.1% decline reported on March 11, 2025. (techdows.com)
The company has been issuing inducement grants under Nasdaq Listing Rule 5635(c)(4), which could lead to shareholder dilution. (globenewswire.com)
While analysts are optimistic, the company's reliance on successful clinical trial outcomes for its gene therapy candidates introduces significant risk if results do not meet expectations. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
SLDB News
AllArticlesVideos
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
GlobeNewsWire·2 weeks ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Solid Biosciences Inc. stock?
Solid Biosciences Inc. (SLDB) has a market cap of $495M as of July 21, 2025.
What is the P/E ratio for Solid Biosciences Inc. stock?
The price to earnings (P/E) ratio for Solid Biosciences Inc. (SLDB) stock is 0 as of July 21, 2025.
Does Solid Biosciences Inc. stock pay dividends?
No, Solid Biosciences Inc. (SLDB) stock does not pay dividends to its shareholders as of July 21, 2025.
When is the next Solid Biosciences Inc. dividend payment date?
Solid Biosciences Inc. (SLDB) stock does not pay dividends to its shareholders.
What is the beta indicator for Solid Biosciences Inc.?
Solid Biosciences Inc. (SLDB) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.